RT @AurelieRheumo: Peresolimab PD-1 agonist in RA Phase 2 RCT Primary endpoint met w/ > improvement DAS28CRP Wk12
Tweet Content
Peresolimab PD-1 agonist in RA Phase 2 RCT
Primary endpoint met w/ > improvement DAS28CRP Wk12
Also greater improvement of CDAI in both treated grps
TEAEs PBO 37% PER 300mg 40% PER 700mg 35%, 1 serious AE in PER 700mg
https://t.co/QtclWIWAw9
Abs#L03 #ACR22 @Rheumnow https://t.co/bLHP4JuNjt
Links
A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis - ACR Meeti…
http://bit.ly/3g91au5
Show on Archive Page
On
Display in Search Results
On
PDQ
Off